DE10109897A1 - Fakultativ kationische Liposomen und Verwendung dieser - Google Patents
Fakultativ kationische Liposomen und Verwendung dieserInfo
- Publication number
- DE10109897A1 DE10109897A1 DE10109897A DE10109897A DE10109897A1 DE 10109897 A1 DE10109897 A1 DE 10109897A1 DE 10109897 A DE10109897 A DE 10109897A DE 10109897 A DE10109897 A DE 10109897A DE 10109897 A1 DE10109897 A1 DE 10109897A1
- Authority
- DE
- Germany
- Prior art keywords
- liposomes
- positive
- membrane
- negative
- charge
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000002502 liposome Substances 0.000 title claims abstract description 101
- 125000002091 cationic group Chemical group 0.000 title description 17
- 239000002800 charge carrier Substances 0.000 claims abstract description 27
- 239000012528 membrane Substances 0.000 claims abstract description 20
- 150000002632 lipids Chemical class 0.000 claims description 18
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 6
- 125000003636 chemical group Chemical group 0.000 claims description 6
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 claims description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-O ammonium group Chemical group [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 claims description 2
- 239000000969 carrier Substances 0.000 claims description 2
- 238000000034 method Methods 0.000 abstract description 2
- WLNARFZDISHUGS-MIXBDBMTSA-N cholesteryl hemisuccinate Chemical compound C1C=C2C[C@@H](OC(=O)CCC(O)=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 WLNARFZDISHUGS-MIXBDBMTSA-N 0.000 description 17
- 102000039446 nucleic acids Human genes 0.000 description 12
- 108020004707 nucleic acids Proteins 0.000 description 12
- 150000007523 nucleic acids Chemical class 0.000 description 12
- 239000000872 buffer Substances 0.000 description 11
- 230000027455 binding Effects 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 10
- 230000007935 neutral effect Effects 0.000 description 10
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 230000004927 fusion Effects 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- 238000004519 manufacturing process Methods 0.000 description 7
- 239000002245 particle Substances 0.000 description 7
- 235000018102 proteins Nutrition 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- 210000002966 serum Anatomy 0.000 description 7
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
- 125000000129 anionic group Chemical group 0.000 description 6
- 150000003904 phospholipids Chemical class 0.000 description 6
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 6
- 108010067770 Endopeptidase K Proteins 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 4
- 230000004568 DNA-binding Effects 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 239000007995 HEPES buffer Substances 0.000 description 4
- 239000013543 active substance Substances 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 239000004417 polycarbonate Substances 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 230000002776 aggregation Effects 0.000 description 3
- 238000004220 aggregation Methods 0.000 description 3
- -1 alkyl homocysteines Chemical class 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- BIABMEZBCHDPBV-UHFFFAOYSA-N dipalmitoyl phosphatidylglycerol Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCCCCCCCCCC BIABMEZBCHDPBV-UHFFFAOYSA-N 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 238000004806 packaging method and process Methods 0.000 description 3
- 230000035699 permeability Effects 0.000 description 3
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 3
- 230000004962 physiological condition Effects 0.000 description 3
- 235000011056 potassium acetate Nutrition 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 230000032258 transport Effects 0.000 description 3
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 2
- 102000004506 Blood Proteins Human genes 0.000 description 2
- 108010017384 Blood Proteins Proteins 0.000 description 2
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 2
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- 229930182558 Sterol Chemical class 0.000 description 2
- 229920004890 Triton X-100 Polymers 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 108010041102 azocasein Proteins 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 238000013270 controlled release Methods 0.000 description 2
- 238000002296 dynamic light scattering Methods 0.000 description 2
- 210000001163 endosome Anatomy 0.000 description 2
- 238000005189 flocculation Methods 0.000 description 2
- 230000016615 flocculation Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000009871 nonspecific binding Effects 0.000 description 2
- 230000008823 permeabilization Effects 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 150000003432 sterols Chemical class 0.000 description 2
- 235000003702 sterols Nutrition 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- YEDNBEGNKOANMB-REOHCLBHSA-N (2r)-2-amino-3-sulfanylpropanamide Chemical compound SC[C@H](N)C(N)=O YEDNBEGNKOANMB-REOHCLBHSA-N 0.000 description 1
- KSXTUUUQYQYKCR-LQDDAWAPSA-M 2,3-bis[[(z)-octadec-9-enoyl]oxy]propyl-trimethylazanium;chloride Chemical compound [Cl-].CCCCCCCC\C=C/CCCCCCCC(=O)OCC(C[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC KSXTUUUQYQYKCR-LQDDAWAPSA-M 0.000 description 1
- XPQIPUZPSLAZDV-UHFFFAOYSA-N 2-pyridylethylamine Chemical compound NCCC1=CC=CC=N1 XPQIPUZPSLAZDV-UHFFFAOYSA-N 0.000 description 1
- 108010016626 Dipeptides Proteins 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical group C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- ATBOMIWRCZXYSZ-XZBBILGWSA-N [1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-hexadecanoyloxypropan-2-yl] (9e,12e)-octadeca-9,12-dienoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C\C\C=C\CCCCC ATBOMIWRCZXYSZ-XZBBILGWSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- IMUDHTPIFIBORV-UHFFFAOYSA-N aminoethylpiperazine Chemical compound NCCN1CCNCC1 IMUDHTPIFIBORV-UHFFFAOYSA-N 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229940125717 barbiturate Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000003850 cellular structure Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- UFULAYFCSOUIOV-UHFFFAOYSA-N cysteamine Chemical compound NCCS UFULAYFCSOUIOV-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 210000000172 cytosol Anatomy 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000012202 endocytosis Effects 0.000 description 1
- 230000001159 endocytotic effect Effects 0.000 description 1
- 238000005188 flotation Methods 0.000 description 1
- 230000000799 fusogenic effect Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000010196 hermaphroditism Effects 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000002101 lytic effect Effects 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- RWIVICVCHVMHMU-UHFFFAOYSA-N n-aminoethylmorpholine Chemical compound NCCN1CCOCC1 RWIVICVCHVMHMU-UHFFFAOYSA-N 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940067605 phosphatidylethanolamines Drugs 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 150000003408 sphingolipids Chemical class 0.000 description 1
- 125000002328 sterol group Chemical group 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000002885 thrombogenetic effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
- A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T428/00—Stock material or miscellaneous articles
- Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
- Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
- Y10T428/2984—Microcapsule with fluid core [includes liposome]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Dispersion Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Preparation (AREA)
- Cosmetics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Priority Applications (19)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10109897A DE10109897A1 (de) | 2001-02-21 | 2001-02-21 | Fakultativ kationische Liposomen und Verwendung dieser |
| AT02701290T ATE363893T1 (de) | 2001-02-21 | 2002-02-21 | Amphotere liposomen und verwendung dieser |
| PCT/EP2002/001880 WO2002066012A2 (de) | 2001-02-21 | 2002-02-21 | Amphotere liposomen und verwendung dieser |
| ES02701290T ES2289079T3 (es) | 2001-02-21 | 2002-02-21 | Liposomas anfotericos y su utilizacion. |
| DE50210271T DE50210271D1 (de) | 2001-02-21 | 2002-02-21 | Amphotere liposomen und verwendung dieser |
| CNB028052137A CN1241549C (zh) | 2001-02-21 | 2002-02-21 | 两性脂质体及其应用 |
| BRPI0207775A BRPI0207775B1 (pt) | 2001-02-21 | 2002-02-21 | lipossomos anfotéricos, método para carregamento dos mesmos com ingredientes ativos e sua utilização |
| US10/081,617 US7371404B2 (en) | 2001-02-21 | 2002-02-21 | Amphoteric liposomes and their use |
| AU2002234643A AU2002234643B2 (en) | 2001-02-21 | 2002-02-21 | Amphoteric liposomes and the use thereof |
| CA2438116A CA2438116C (en) | 2001-02-21 | 2002-02-21 | Amphoteric liposomes and the use thereof |
| JP2002565572A JP2004525898A (ja) | 2001-02-21 | 2002-02-21 | 両性リポソーム及びその使用 |
| EP02701290A EP1363601B1 (de) | 2001-02-21 | 2002-02-21 | Amphotere liposomen und verwendung dieser |
| US11/590,143 US20070269504A1 (en) | 2001-02-21 | 2006-10-31 | Amphoteric liposomes |
| US11/590,357 US7780983B2 (en) | 2001-02-21 | 2006-10-31 | Amphoteric liposomes |
| US12/806,342 US20110293695A1 (en) | 2001-02-21 | 2010-08-09 | Amphoteric liposomes |
| JP2010211089A JP5480764B2 (ja) | 2001-02-21 | 2010-09-21 | 両性リポソーム及びその使用 |
| JP2013237869A JP2014031383A (ja) | 2001-02-21 | 2013-11-18 | 両性リポソーム及びその使用 |
| JP2014165961A JP2014218520A (ja) | 2001-02-21 | 2014-08-18 | 両性リポソーム及びその使用 |
| JP2016001813A JP2016104786A (ja) | 2001-02-21 | 2016-01-07 | 両性リポソーム及びその使用 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10109897A DE10109897A1 (de) | 2001-02-21 | 2001-02-21 | Fakultativ kationische Liposomen und Verwendung dieser |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE10109897A1 true DE10109897A1 (de) | 2002-11-07 |
Family
ID=7675950
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE10109897A Withdrawn DE10109897A1 (de) | 2001-02-21 | 2001-02-21 | Fakultativ kationische Liposomen und Verwendung dieser |
| DE50210271T Expired - Lifetime DE50210271D1 (de) | 2001-02-21 | 2002-02-21 | Amphotere liposomen und verwendung dieser |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE50210271T Expired - Lifetime DE50210271D1 (de) | 2001-02-21 | 2002-02-21 | Amphotere liposomen und verwendung dieser |
Country Status (11)
| Country | Link |
|---|---|
| US (4) | US7371404B2 (enExample) |
| EP (1) | EP1363601B1 (enExample) |
| JP (5) | JP2004525898A (enExample) |
| CN (1) | CN1241549C (enExample) |
| AT (1) | ATE363893T1 (enExample) |
| AU (1) | AU2002234643B2 (enExample) |
| BR (1) | BRPI0207775B1 (enExample) |
| CA (1) | CA2438116C (enExample) |
| DE (2) | DE10109897A1 (enExample) |
| ES (1) | ES2289079T3 (enExample) |
| WO (1) | WO2002066012A2 (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10207177A1 (de) * | 2002-02-19 | 2003-09-04 | Novosom Ag | Fakultativ kationische Lipide |
Families Citing this family (136)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10109897A1 (de) * | 2001-02-21 | 2002-11-07 | Novosom Ag | Fakultativ kationische Liposomen und Verwendung dieser |
| US7858117B2 (en) * | 2002-02-21 | 2010-12-28 | Novosom Ag | Amphoteric liposomes and their use |
| CA2487274A1 (en) * | 2002-05-06 | 2003-11-13 | Nucleonics Inc. | Spermine chemically linked to lipids and cell-specific targeting molecules as a transfection agent |
| US7718189B2 (en) | 2002-10-29 | 2010-05-18 | Transave, Inc. | Sustained release of antiinfectives |
| DE10255106A1 (de) * | 2002-11-24 | 2004-06-09 | Novosom Ag | Liposomale Glucocorticoide |
| EP1547580A1 (en) * | 2003-12-23 | 2005-06-29 | MediGene Oncology GmbH | Loading of a camptothecin drug into colloidal nanoparticles |
| DE102004054730A1 (de) | 2004-03-28 | 2006-05-11 | Novosom Ag | Serumstabile amphotere Liposomen |
| US8815599B2 (en) | 2004-06-01 | 2014-08-26 | Pronai Therapeutics, Inc. | Methods and compositions for the inhibition of gene expression |
| AU2005300638A1 (en) * | 2004-11-05 | 2006-05-11 | Novosom Ag | Improvements in or relating to pharmaceutical compositions comprising an oligonucleotide as an active agent |
| EP1764090A1 (en) * | 2005-09-15 | 2007-03-21 | Novosom AG | Amphoteric liposomes for local drug applications |
| EP1811960A2 (en) * | 2004-11-19 | 2007-08-01 | Novosom AG | Improvements in or relating to pharmaceutical compositions for local administration |
| EP1676569A1 (en) * | 2004-12-30 | 2006-07-05 | Pevion Biotech Ltd. | Lyophilization of virosomes |
| EP1764091B1 (en) * | 2005-09-15 | 2017-08-30 | Marina Biotech, Inc. | Improvements in or relating to amphoteric liposomes |
| US20120021042A1 (en) * | 2005-09-15 | 2012-01-26 | Steffen Panzner | Efficient Method For Loading Amphoteric Liposomes With Nucleic Acid Active Substances |
| US20080088046A1 (en) * | 2006-10-13 | 2008-04-17 | Steffen Panzner | Amphoteric liposomes, a method of formulating an amphoteric liposome and a method of loading an amphoteric liposome |
| EP1911443A1 (en) * | 2006-10-13 | 2008-04-16 | Novosom AG | Amphoteric liposomes, method of formulating an amphoteric liposome and a method of loading an amphoteric liposome |
| EP1764089A1 (en) * | 2005-09-15 | 2007-03-21 | Novosom AG | Serum stable liposomes comprising amphoter II lipid mixtures |
| EP1934348B1 (en) * | 2005-10-11 | 2018-05-02 | Ben-Gurion University Of The Negev Research And Development Authority | Compositions for silencing the expression of vdac1 and uses thereof |
| US20090324587A1 (en) | 2005-12-01 | 2009-12-31 | Neal Clifford Goodwin | Cancer Therapies and Pharmaceutical Compositions Used Therein |
| JP5122474B2 (ja) * | 2005-12-01 | 2013-01-16 | プロネイ・セラピューティクス・インコーポレイテッド | 両性リポソーム製剤 |
| ES2798263T3 (es) | 2005-12-08 | 2020-12-10 | Insmed Inc | Composiciones a base de lípidos de antiinfecciosos para tratar infecciones pulmonares |
| WO2007117550A2 (en) * | 2006-04-06 | 2007-10-18 | Transave, Inc. | Methods for coacervation induced liposomal encapsulation and formulations thereof |
| US20140178462A1 (en) * | 2006-10-13 | 2014-06-26 | Marina Biotech, Inc. | Amphoteric liposomes comprising neutral lipids |
| AU2007306556B2 (en) * | 2006-10-13 | 2014-04-10 | Marina Biotech, Inc. | Improvements in or relating to amphoteric liposomes |
| JP2010513354A (ja) * | 2006-12-19 | 2010-04-30 | ノヴォソム アクチェンゲゼルシャフト | トランスフェクションエンハンサー要素を含む脂質および脂質集合体 |
| WO2008118013A2 (en) | 2007-03-23 | 2008-10-02 | To-Bbb Holding B.V. | Targeted intracellular delivery of antiviral agents |
| US20080260895A1 (en) * | 2007-04-17 | 2008-10-23 | Vermeire Drew A | Milk replacer composition and product and method for producing the same |
| WO2008137717A1 (en) | 2007-05-04 | 2008-11-13 | Transave, Inc. | Compositions of multicationic drugs for reducing interactions with polyanionic biomolecules and methods and uses thereof |
| EP3434259A1 (en) | 2007-05-04 | 2019-01-30 | Marina Biotech, Inc. | Amino acid lipids and uses thereof |
| US9114081B2 (en) | 2007-05-07 | 2015-08-25 | Insmed Incorporated | Methods of treating pulmonary disorders with liposomal amikacin formulations |
| US9119783B2 (en) | 2007-05-07 | 2015-09-01 | Insmed Incorporated | Method of treating pulmonary disorders with liposomal amikacin formulations |
| DE102007029471A1 (de) | 2007-06-20 | 2008-12-24 | Novosom Ag | Neue fakultativ kationische Sterole |
| WO2008154700A1 (en) | 2007-06-20 | 2008-12-24 | Phylogica Limited | Compositions and uses thereof for the treatment of acute respiratory distress syndrome (ards) and clinical disorders associated with therewith |
| EP2200586B1 (en) * | 2007-09-07 | 2019-11-13 | Synvolux IP B.V. | Improved liposomes and uses thereof |
| CA2702103A1 (en) * | 2007-10-12 | 2009-04-16 | Novosom Ag | Improvements in or relating to amphotaric liposomes comprising neutral lipids |
| WO2009149418A2 (en) * | 2008-06-06 | 2009-12-10 | Asuragen, Inc. | Novel compositions for the in vivo delivery of rnai agents |
| CN104382853A (zh) | 2008-10-16 | 2015-03-04 | 玛瑞纳生物技术有限公司 | 基因沉默治疗剂的脂质体有效递送方法和组合物 |
| JP5392707B2 (ja) * | 2009-03-31 | 2014-01-22 | 株式会社Ｎｔｔドコモ | 膜小胞分裂システム |
| US20120107389A1 (en) * | 2009-03-31 | 2012-05-03 | Jayanta Bhattacharyya | Amphoteric liposomal compositions for cellular delivery of small rna molecules for use in rna interference |
| WO2010135714A2 (en) | 2009-05-22 | 2010-11-25 | The Methodist Hospital Research Institute | Methods for modulating adipocyte expression using microrna compositions |
| ES2386855T3 (es) * | 2009-07-09 | 2012-09-03 | Marina Biotech, Inc. | Emulación de estructuras de lipoproteínas |
| AU2010270337B2 (en) | 2009-07-09 | 2016-09-22 | Biontech Delivery Technologies Gmbh | Amphoteric liposomes comprising imino lipids |
| SI2506857T1 (en) | 2009-12-01 | 2018-08-31 | Translate Bio, Inc. | Delivery of mRNA for the enrichment of proteins and enzymes in human genetic diseases |
| WO2011120023A1 (en) | 2010-03-26 | 2011-09-29 | Marina Biotech, Inc. | Nucleic acid compounds for inhibiting survivin gene expression uses thereof |
| WO2011133584A2 (en) | 2010-04-19 | 2011-10-27 | Marina Biotech, Inc. | Nucleic acid compounds for inhibiting hras gene expression and uses thereof |
| WO2011139842A2 (en) | 2010-04-28 | 2011-11-10 | Marina Biotech, Inc. | Nucleic acid compounds for inhibiting fgfr3 gene expression and uses thereof |
| CA2807552A1 (en) | 2010-08-06 | 2012-02-09 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| EP2857499A1 (en) | 2010-10-01 | 2015-04-08 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| US8853377B2 (en) | 2010-11-30 | 2014-10-07 | Shire Human Genetic Therapies, Inc. | mRNA for use in treatment of human genetic diseases |
| WO2012109495A1 (en) | 2011-02-09 | 2012-08-16 | Metabolic Solutions Development Company, Llc | Cellular targets of thiazolidinediones |
| CA2831613A1 (en) | 2011-03-31 | 2012-10-04 | Moderna Therapeutics, Inc. | Delivery and formulation of engineered nucleic acids |
| WO2012159164A1 (en) | 2011-05-23 | 2012-11-29 | Phylogica Limited | Method of determining, identifying or isolating cell-penetrating peptides |
| KR20220025112A (ko) | 2011-06-08 | 2022-03-03 | 샤이어 휴먼 지네틱 테라피즈 인크. | Mrna 전달을 위한 지질 나노입자 조성물 및 방법 |
| US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| PT3682905T (pt) | 2011-10-03 | 2022-04-07 | Modernatx Inc | Nucleósidos, nucleótidos e ácidos nucleicos modificados e respetivas utilizações |
| ES2923757T3 (es) | 2011-12-16 | 2022-09-30 | Modernatx Inc | Composiciones de ARNm modificado |
| CN102532259A (zh) * | 2012-03-09 | 2012-07-04 | 中国药科大学 | 基于寡肽的阳离子脂质衍生物及在药剂制剂中的应用 |
| WO2013151664A1 (en) | 2012-04-02 | 2013-10-10 | modeRNA Therapeutics | Modified polynucleotides for the production of proteins |
| CN102603866B (zh) * | 2012-03-15 | 2014-01-15 | 中国药科大学 | 基于寡肽的pH敏感型两性离子及其在药剂中的应用 |
| US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
| US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
| US10501512B2 (en) | 2012-04-02 | 2019-12-10 | Modernatx, Inc. | Modified polynucleotides |
| PL2852391T3 (pl) | 2012-05-21 | 2022-04-11 | Insmed Incorporated | Układy do leczenia infekcji płuc |
| EP3536787A1 (en) | 2012-06-08 | 2019-09-11 | Translate Bio, Inc. | Nuclease resistant polynucleotides and uses thereof |
| WO2013186793A1 (en) * | 2012-06-11 | 2013-12-19 | Council Of Scientific & Industrial Research | Rice bran-lipids based formulation and process for preparation thereof for selective delivery of genes to cancer cells |
| AU2013340414B2 (en) | 2012-10-23 | 2019-05-02 | Caris Science, Inc. | Aptamers and uses thereof |
| US10942184B2 (en) | 2012-10-23 | 2021-03-09 | Caris Science, Inc. | Aptamers and uses thereof |
| CN104884637A (zh) | 2012-11-05 | 2015-09-02 | 普隆奈治疗公司 | 利用生物标志物通过bcl2表达的调节治疗癌症的方法 |
| PT2922554T (pt) | 2012-11-26 | 2022-06-28 | Modernatx Inc | Arn modificado nas porções terminais |
| CA2891487A1 (en) | 2012-11-29 | 2014-06-05 | Insmed Incorporated | Stabilized vancomycin formulations |
| AU2013361323B2 (en) | 2012-12-19 | 2018-09-06 | Caris Science, Inc. | Compositions and methods for aptamer screening |
| EA201591229A1 (ru) | 2013-03-14 | 2016-01-29 | Шир Хьюман Дженетик Терапис, Инк. | Способы очистки матричной рнк |
| KR102311614B1 (ko) | 2013-03-14 | 2021-10-08 | 샤이어 휴먼 지네틱 테라피즈 인크. | Cftr mrna 조성물 및 관련 방법 및 사용 |
| WO2014143855A2 (en) | 2013-03-15 | 2014-09-18 | Mirna Therapeutics, Inc. | Combination cancer treatments utilizing micrornas and egfr-tki inhibitors |
| US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
| JP2016530232A (ja) | 2013-06-24 | 2016-09-29 | ミルナ セラピューティクス，インク． | Ｍｉｒ−３４活性のバイオマーカー |
| JP5914418B2 (ja) | 2013-06-26 | 2016-05-11 | 富士フイルム株式会社 | 脂質粒子、核酸送達キャリア、核酸送達キャリア製造用組成物、脂質粒子の製造方法及び遺伝子導入方法 |
| US10023626B2 (en) | 2013-09-30 | 2018-07-17 | Modernatx, Inc. | Polynucleotides encoding immune modulating polypeptides |
| KR20160067219A (ko) | 2013-10-03 | 2016-06-13 | 모더나 세라퓨틱스, 인코포레이티드 | 저밀도 지단백질 수용체를 암호화하는 폴리뉴클레오타이드 |
| ES2707966T3 (es) | 2013-10-22 | 2019-04-08 | Translate Bio Inc | Terapia de ARNm para la deficiencia en síntesis de argininosuccinato |
| EP3574923A1 (en) | 2013-10-22 | 2019-12-04 | Translate Bio, Inc. | Mrna therapy for phenylketonuria |
| EP3126496A1 (en) | 2014-04-01 | 2017-02-08 | Mirna Therapeutics, Inc. | Microrna dosing regimens |
| HRP20220070T1 (hr) | 2014-04-23 | 2022-04-01 | Modernatx, Inc. | Cjepiva nukleinske kiseline |
| EP4729528A3 (en) | 2014-04-25 | 2026-06-24 | Translate Bio, Inc. | Methods for purification of messenger rna |
| MX384843B (es) | 2014-05-15 | 2025-03-14 | Insmed Inc | Métodos para tratar infecciones pulmonares micobacterianas no tuberculosas. |
| JP6240570B2 (ja) | 2014-07-17 | 2017-11-29 | 富士フイルム株式会社 | 脂質粒子および核酸送達キャリア |
| US10722599B2 (en) | 2015-02-04 | 2020-07-28 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Lipid assemblies and uses thereof and some pH and electrostatic modulating lipids to be used in said assemblies |
| WO2017031232A1 (en) | 2015-08-17 | 2017-02-23 | Modernatx, Inc. | Methods for preparing particles and related compositions |
| HRP20220156T1 (hr) | 2015-09-17 | 2022-04-15 | Modernatx, Inc. | Spojevi i pripravci za unutarstaničnu isporuku terapeutskih sredstava |
| DK3386484T3 (da) | 2015-12-10 | 2022-07-04 | Modernatx Inc | Sammensætninger og fremgangsmåder til afgivelse af terapeutiske midler |
| RS63051B1 (sr) | 2015-12-22 | 2022-04-29 | Modernatx Inc | Jedinjenja i kompozicije za intracelularnu isporuku agenasa |
| EP3538067A1 (en) | 2016-11-08 | 2019-09-18 | Modernatx, Inc. | Stabilized formulations of lipid nanoparticles |
| MX2019010155A (es) | 2017-02-27 | 2020-12-10 | Translate Bio Inc | Arnm de cftr optimizado por codón novedoso. |
| JP7332478B2 (ja) | 2017-03-15 | 2023-08-23 | モデルナティエックス インコーポレイテッド | 脂質ナノ粒子製剤 |
| RS63953B1 (sr) | 2017-03-15 | 2023-02-28 | Modernatx Inc | Jedinjenje i kompozicije za intracelularnu isporuku terapeutskih sredstava |
| WO2018170322A1 (en) | 2017-03-15 | 2018-09-20 | Modernatx, Inc. | Crystal forms of amino lipids |
| IL270631B2 (en) | 2017-05-16 | 2024-03-01 | Translate Bio Inc | Treatment of cystic fibrosis by delivery of codon-optimized mrna encoding cftr |
| EP3638678B1 (en) | 2017-06-14 | 2025-12-03 | ModernaTX, Inc. | Compounds and compositions for intracellular delivery of agents |
| MA49421A (fr) | 2017-06-15 | 2020-04-22 | Modernatx Inc | Formulations d'arn |
| MX2020002348A (es) | 2017-08-31 | 2020-10-08 | Modernatx Inc | Métodos de elaboración de nanopartículas lipídicas. |
| KR20200050982A (ko) * | 2017-09-04 | 2020-05-12 | 이치마루 화루코스 가부시키가이샤 | pH 감수성 리포솜 및 그 제조 방법 |
| WO2019048645A1 (en) | 2017-09-08 | 2019-03-14 | Mina Therapeutics Limited | STABILIZED COMPOSITIONS OF SMALL ACTIVATOR RNA (PARNA) FROM CEBPA AND METHODS OF USE |
| HRP20260181T1 (hr) * | 2017-10-20 | 2026-03-27 | BioNTech SE | Priprema i skladištenje lipozomskih rnk formulacija koje su pogodne za terapiju |
| TW201936201A (zh) | 2017-12-14 | 2019-09-16 | 美商堅固生物科技公司 | 基因之非病毒生產及遞送 |
| EP3773505B1 (en) | 2018-03-30 | 2026-04-29 | Insmed Incorporated | Methods for continuous manufacture of liposomal drug products |
| US11566246B2 (en) | 2018-04-12 | 2023-01-31 | Mina Therapeutics Limited | SIRT1-saRNA compositions and methods of use |
| EP3787602A4 (en) | 2018-05-02 | 2022-03-23 | Insmed Incorporated | PROCESS FOR THE MANUFACTURE OF LIPOSOMAL DRUG FORMULATIONS |
| US20190381034A1 (en) * | 2018-06-14 | 2019-12-19 | Ming Fang | Pharmaceutical composition and method for acute on chronic liver failure and related liver diseases |
| US11174500B2 (en) | 2018-08-24 | 2021-11-16 | Translate Bio, Inc. | Methods for purification of messenger RNA |
| CA3110661A1 (en) | 2018-08-29 | 2020-03-05 | University Of Massachusetts | Inhibition of protein kinases to treat friedreich ataxia |
| US12151029B2 (en) | 2018-09-19 | 2024-11-26 | Modernatx, Inc. | PEG lipids and uses thereof |
| CN112996854B (zh) | 2018-09-19 | 2024-08-30 | 摩登纳特斯有限公司 | 高纯度peg脂质和其用途 |
| EP3853202A1 (en) | 2018-09-19 | 2021-07-28 | ModernaTX, Inc. | Compounds and compositions for intracellular delivery of therapeutic agents |
| US12090235B2 (en) | 2018-09-20 | 2024-09-17 | Modernatx, Inc. | Preparation of lipid nanoparticles and methods of administration thereof |
| AU2019384557B2 (en) | 2018-11-21 | 2025-07-17 | Translate Bio, Inc. | Treatment of cystic fibrosis by delivery of nebulized mRNA encoding CFTR |
| CN113939282A (zh) | 2019-01-31 | 2022-01-14 | 摩登纳特斯有限公司 | 制备脂质纳米颗粒的方法 |
| EP3953473A1 (en) | 2019-04-12 | 2022-02-16 | MiNA Therapeutics Limited | Sirt1-sarna compositions and methods of use |
| AU2020351220A1 (en) | 2019-09-19 | 2022-04-07 | Modernatx, Inc. | Carbonate containing lipid compounds and compositions for intracellular delivery of therapeutic agents |
| EP4031524A1 (en) | 2019-09-19 | 2022-07-27 | ModernaTX, Inc. | Branched tail lipid compounds and compositions for intracellular delivery of therapeutic agents |
| CA3155003A1 (en) | 2019-09-20 | 2021-03-25 | Translate Bio, Inc. | Mrna encoding engineered cftr |
| US12115230B2 (en) | 2020-04-09 | 2024-10-15 | Verve Therapeutics, Inc. | Base editing of ANGPTL3 and methods of using same for treatment of disease |
| WO2021255262A1 (en) | 2020-06-19 | 2021-12-23 | Sylentis Sau | siRNA AND COMPOSITIONS FOR PROPHYLACTIC AND THERAPEUTIC TREATMENT OF VIRUS DISEASES |
| WO2022060871A1 (en) | 2020-09-15 | 2022-03-24 | Verve Therapeutics, Inc. | Lipid formulations for gene editing |
| GB2603454A (en) | 2020-12-09 | 2022-08-10 | Ucl Business Ltd | Novel therapeutics for the treatment of neurodegenerative disorders |
| EP4015634A1 (en) | 2020-12-15 | 2022-06-22 | Sylentis, S.A.U. | Sirna and compositions for prophylactic and therapeutic treatment of virus diseases |
| US11524023B2 (en) | 2021-02-19 | 2022-12-13 | Modernatx, Inc. | Lipid nanoparticle compositions and methods of formulating the same |
| US20240175033A1 (en) | 2021-03-26 | 2024-05-30 | Mina Therapeutics Limited | TMEM173 saRNA Compositions and Methods of Use |
| WO2023099884A1 (en) | 2021-12-01 | 2023-06-08 | Mina Therapeutics Limited | Pax6 sarna compositions and methods of use |
| GB202117758D0 (en) | 2021-12-09 | 2022-01-26 | Ucl Business Ltd | Therapeutics for the treatment of neurodegenerative disorders |
| WO2023170435A1 (en) | 2022-03-07 | 2023-09-14 | Mina Therapeutics Limited | Il10 sarna compositions and methods of use |
| TW202440929A (zh) | 2022-12-14 | 2024-10-16 | 加拿大商普羅維登斯治療控股公司 | 用於感染性疾病的組合物和方法 |
| US20260218178A1 (en) | 2022-12-22 | 2026-07-30 | Mina Therapeutics Limited | Chemically Modified saRNA Compositions and Methods of Use |
| IL321425A (en) | 2022-12-23 | 2025-08-01 | Biontech Delivery Tech Gmbh | compound |
| KR20260065891A (ko) | 2023-09-01 | 2026-05-11 | 노보아크 게엠베하 | 핵산 카고 및 이온화가능한 지질을 갖는 지질 나노입자 |
| CN122535391A (zh) * | 2023-12-22 | 2026-08-07 | 科蒂公司 | 用于将功能剂递送到皮肤的阳离子微囊泡和功能化外泌体样载体 |
| WO2026027887A2 (en) | 2024-08-02 | 2026-02-05 | Mina Therapeutics Limited | Hbg1/2-sarna compositions and methods of use |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4599227A (en) * | 1983-11-07 | 1986-07-08 | Wisconsin Alumni Research Foundation | Injectable pharmaceutical preparation for the induction of multiple follicular growth |
| US4891208A (en) | 1985-04-10 | 1990-01-02 | The Liposome Company, Inc. | Steroidal liposomes |
| US5283122A (en) * | 1984-04-19 | 1994-02-01 | University Of Tennessee Research Corporation | Fused liposome and acid induced method for liposome fusion |
| ATE45744T1 (de) | 1984-07-25 | 1989-09-15 | Ciba Geigy Ag | Phosphatidylverbindungen, verfahren zu ihrer herstellung und ihre verwendung. |
| US5077211A (en) * | 1988-07-06 | 1991-12-31 | Applied Genetics, Inc. | Purification and administration of dna repair enzymes |
| US5290563A (en) * | 1989-07-27 | 1994-03-01 | Laboratoire Des Stallergenes | Method for combining a mixture of heterogeneous substances with liposomes |
| US5165994A (en) | 1990-06-05 | 1992-11-24 | University Of Delaware | Spontaneous equilbrium surfactant vesicles |
| US5302389A (en) * | 1992-08-17 | 1994-04-12 | Board Of Regents, The University Of Texas System | Method for treating UV-induced suppression of contact hypersensitivity by administration of T4 endonuclease |
| JP2950520B2 (ja) * | 1993-04-02 | 1999-09-20 | アンティキャンサー インコーポレーテド | 毛胞に有益な配合物を送達する方法 |
| US5993850A (en) * | 1994-09-13 | 1999-11-30 | Skyepharma Inc. | Preparation of multivesicular liposomes for controlled release of encapsulated biologically active substances |
| US5981501A (en) * | 1995-06-07 | 1999-11-09 | Inex Pharmaceuticals Corp. | Methods for encapsulating plasmids in lipid bilayers |
| US6258792B1 (en) * | 1996-04-12 | 2001-07-10 | University Of Pittsburgh | Cationic cholesteryl derivatives containing cyclic polar groups |
| ES2165050T3 (es) * | 1996-04-12 | 2002-03-01 | Univ Pittsburgh | Nuevos derivados cationicos de colesterilo que contienen grupos polares ciclicos. |
| EP0938298B1 (en) * | 1996-09-13 | 2002-12-04 | Lipoxen Technologies Limited | Liposome-based composition |
| US7384923B2 (en) * | 1999-05-14 | 2008-06-10 | Lipoxen Technologies Limited | Liposomes |
| US5962015A (en) * | 1997-05-02 | 1999-10-05 | Kobo Products S.A.R.L. | Stabilized liposomes |
| CA2289702C (en) * | 1997-05-14 | 2008-02-19 | Inex Pharmaceuticals Corp. | High efficiency encapsulation of charged therapeutic agents in lipid vesicles |
| AU8525098A (en) * | 1997-07-24 | 1999-02-16 | Inex Pharmaceuticals Corporation | Liposomal compositions for the delivery of nucleic acid catalysts |
| FR2766706B1 (fr) * | 1997-07-30 | 2001-05-25 | Biovector Therapeutics Sa | Complexes particulaires stables de charge globale neutre ou negative de structure multilamellaire composes par au moins une substance biologiquement active globalement anionique et un constituant cationique, leur preparation et utilisation |
| US6106858A (en) * | 1997-09-08 | 2000-08-22 | Skyepharma, Inc. | Modulation of drug loading in multivescular liposomes |
| JPH11302199A (ja) * | 1998-04-16 | 1999-11-02 | Sankyo Co Ltd | 薬物運搬体を構成するグラフト共重合体 |
| JP2000198731A (ja) * | 1998-10-29 | 2000-07-18 | Sankyo Co Ltd | 毒性の低減されたリポソ―ム |
| DE19852928C1 (de) | 1998-11-17 | 2000-08-03 | Steffen Panzner | Strukturen in Form von Hohlkugeln |
| US6379698B1 (en) * | 1999-04-06 | 2002-04-30 | Isis Pharmaceuticals, Inc. | Fusogenic lipids and vesicles |
| DE10010264A1 (de) | 2000-03-02 | 2001-09-13 | Novosom Gmbh | Stabilisierte Liposomen und Hüllstrukturen |
| DE10109897A1 (de) * | 2001-02-21 | 2002-11-07 | Novosom Ag | Fakultativ kationische Liposomen und Verwendung dieser |
| US7858117B2 (en) * | 2002-02-21 | 2010-12-28 | Novosom Ag | Amphoteric liposomes and their use |
| EP1764091B1 (en) * | 2005-09-15 | 2017-08-30 | Marina Biotech, Inc. | Improvements in or relating to amphoteric liposomes |
-
2001
- 2001-02-21 DE DE10109897A patent/DE10109897A1/de not_active Withdrawn
-
2002
- 2002-02-21 BR BRPI0207775A patent/BRPI0207775B1/pt not_active IP Right Cessation
- 2002-02-21 EP EP02701290A patent/EP1363601B1/de not_active Expired - Lifetime
- 2002-02-21 ES ES02701290T patent/ES2289079T3/es not_active Expired - Lifetime
- 2002-02-21 CA CA2438116A patent/CA2438116C/en not_active Expired - Lifetime
- 2002-02-21 JP JP2002565572A patent/JP2004525898A/ja active Pending
- 2002-02-21 DE DE50210271T patent/DE50210271D1/de not_active Expired - Lifetime
- 2002-02-21 US US10/081,617 patent/US7371404B2/en not_active Expired - Lifetime
- 2002-02-21 WO PCT/EP2002/001880 patent/WO2002066012A2/de not_active Ceased
- 2002-02-21 AT AT02701290T patent/ATE363893T1/de active
- 2002-02-21 CN CNB028052137A patent/CN1241549C/zh not_active Expired - Fee Related
- 2002-02-21 AU AU2002234643A patent/AU2002234643B2/en not_active Ceased
-
2006
- 2006-10-31 US US11/590,143 patent/US20070269504A1/en not_active Abandoned
- 2006-10-31 US US11/590,357 patent/US7780983B2/en not_active Expired - Lifetime
-
2010
- 2010-08-09 US US12/806,342 patent/US20110293695A1/en not_active Abandoned
- 2010-09-21 JP JP2010211089A patent/JP5480764B2/ja not_active Expired - Fee Related
-
2013
- 2013-11-18 JP JP2013237869A patent/JP2014031383A/ja active Pending
-
2014
- 2014-08-18 JP JP2014165961A patent/JP2014218520A/ja active Pending
-
2016
- 2016-01-07 JP JP2016001813A patent/JP2016104786A/ja active Pending
Non-Patent Citations (6)
| Title |
|---|
| Budker et al.: Nat. Biotechnol. (1996) 14(6), S. 760-64 * |
| Chu et al.: J. of Liposome Research 4(1), S. 361-395 (1994) * |
| Couvreur et al,: J. of Liposome Research 7(1), S. 1-18 (1997) * |
| Hafez et al.: Biochim. Biophys. Acta 1463, S. 107-114 (2000), Abstr. * |
| Hafez et al.: Biophys. J. 79, S. 1438-46 (2000) Abstr. * |
| Ropert et al.: Delivery Strategies Antisense Oligonucleotide Ther. (1995), S. 233-45 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10207177A1 (de) * | 2002-02-19 | 2003-09-04 | Novosom Ag | Fakultativ kationische Lipide |
Also Published As
| Publication number | Publication date |
|---|---|
| DE50210271D1 (de) | 2007-07-19 |
| US20070269504A1 (en) | 2007-11-22 |
| AU2002234643B2 (en) | 2007-06-21 |
| CA2438116C (en) | 2011-10-11 |
| WO2002066012A3 (de) | 2002-12-19 |
| ES2289079T3 (es) | 2008-02-01 |
| CN1492756A (zh) | 2004-04-28 |
| JP2011021026A (ja) | 2011-02-03 |
| US7780983B2 (en) | 2010-08-24 |
| JP5480764B2 (ja) | 2014-04-23 |
| US20070252295A1 (en) | 2007-11-01 |
| ATE363893T1 (de) | 2007-06-15 |
| US20030099697A1 (en) | 2003-05-29 |
| US20110293695A1 (en) | 2011-12-01 |
| BR0207775A (pt) | 2004-03-30 |
| EP1363601A2 (de) | 2003-11-26 |
| JP2004525898A (ja) | 2004-08-26 |
| JP2016104786A (ja) | 2016-06-09 |
| US7371404B2 (en) | 2008-05-13 |
| JP2014031383A (ja) | 2014-02-20 |
| EP1363601B1 (de) | 2007-06-06 |
| CN1241549C (zh) | 2006-02-15 |
| JP2014218520A (ja) | 2014-11-20 |
| WO2002066012A2 (de) | 2002-08-29 |
| CA2438116A1 (en) | 2002-08-29 |
| BRPI0207775B1 (pt) | 2015-10-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1363601B1 (de) | Amphotere liposomen und verwendung dieser | |
| DE10109898A1 (de) | Lipide mit veränderlicher Ladung | |
| DE19852928C1 (de) | Strukturen in Form von Hohlkugeln | |
| US7858117B2 (en) | Amphoteric liposomes and their use | |
| EP1289642B2 (de) | Nanokapseln mit einer polyelektrolythülle | |
| Hirai et al. | Accumulation of liposome with Sialyl Lewis X to inflammation and tumor region: application to in vivo bio-imaging | |
| EP1397200B1 (de) | Auflösbare nano- und mikrokapseln, verfahren zu ihrer herstellung sowie ihre verwendung | |
| DD201973A5 (de) | Verfahren zur herstellung von liposomalen arzneimitteln | |
| EP2451441A2 (de) | Mischung amphipathischer moleküle und verfahren zur zellmembranmodifikation durch fusion | |
| EP1325334B1 (de) | Verfahren zur immobilisierung von lipidschichten | |
| DE19954843C2 (de) | Verfahren zur Verkapselung von Proteinen oder Peptiden in Liposomen, mit dem Verfahren hergestellte Liposomen und deren Verwendung | |
| DE3610873A1 (de) | Phospholipid-vesikel und verfahren zu ihrer herstellung | |
| WO2006100060A2 (de) | Kolloidale nanokomposite aus lbl-partikeln, lipiden und biologischen komponenten sowie verfahren zur herstllung derselben | |
| DE68903796T2 (de) | Lipidmembranstrukturen. | |
| Hume | A comparative study of niosomes (non-ionic surfactant vesicles) and liposomes: their stability in biological environments | |
| DE102009052404A1 (de) | System und Verfahren zum Screenen von Kandidatenverbindungen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| OP8 | Request for examination as to paragraph 44 patent law | ||
| 8181 | Inventor (new situation) |
Inventor name: PANZNER, STEFFEN, DR., 06108 HALLE, DE Inventor name: FANKHÄNEL, STEFAN, 06114 HALLE, DE |
|
| 8180 | Miscellaneous part 1 |
Free format text: IN DER ZUSAMMENFASSUNG IST DAS WORT "VERFAHREN" ZU STREICHEN |
|
| 8139 | Disposal/non-payment of the annual fee |